Advertisement
Canada markets closed
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7324
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     
  • Bitcoin CAD

    88,249.87
    +534.49 (+0.61%)
     
  • CMC Crypto 200

    1,391.86
    +9.29 (+0.67%)
     
  • GOLD FUTURES

    2,346.00
    +3.50 (+0.15%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,773.00
    +205.50 (+1.17%)
     
  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,786.65
    +158.17 (+0.42%)
     
  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

What Analysts Recommend for Accuray in February 2018

What Analysts Recommend for Accuray in February 2018

Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.